Article Information
PubMed
History
- Received March 30, 2010
- Revision received June 2, 2010
- Revision received June 22, 2010
- Accepted June 24, 2010
- Published online March 1, 2011.
Copyright & Usage
© 2011 Canadian Medical Association
Author Information
- Olivia Dean, BSc, PhD⇑,
- Frank Giorlando, MBBS, BMedSc,
- Michael Berk, MBBCh, MMed(Psych), PhD
- Dean, Berk — Mental Health Research Institute, Parkville; Dean, Giorlando, Berk — Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong; Berk — Youth Health Orygen Research Centre, Parkville, and the School of Medicine, Faculty of Health, Medicine, Nursing and Behavioural Sciences, Deakin University, Geelong, Victoria, Australia
- Correspondence to: Dr. O. Dean, Mental Health Research Institute, 155 Oak St., Parkville, Victoria, Australia; oliviad{at}barwonhealth.org.au
Cited By...
In this issue
Article tools
Respond to this article
Related Articles
Cited By...
- NAMPT-derived NAD+ fuels PARP1 to promote skin inflammation through parthanatos
- Vitamin D and Depression: Cellular and Regulatory Mechanisms
- Acetylcysteine for treatment of autism spectrum disorder symptoms
- Oral acetylcysteine for neuropsychiatric disorders
- N-Acetylcysteine- and MK-801-Induced Changes in Glutamate Levels Do Not Affect In Vivo Binding of Metabotropic Glutamate 5 Receptor Radioligand 11C-ABP688 in Rat Brain